Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Numbers of participants per visit are listed in Table 2. (A) Calcium; (B) Phosphate, significant within-group difference in the Pycnogenol® group between baseline and 6 months; (C) Alkaline phosphatase (ALP); (D) Vitamin D; (E) Parathyroid hormone 1 to 84 (PTH), significant between-group difference at 3 months; (F) Intact fibroblast growth factor-23 (iFGF-23).

Source: Mineral metabolism markers. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Quality of life and safety of a dietary intervention with French maritime pine bark extract (Pycnogenol®) in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study: Part II

Source: Article title.

The study followed the principles of the Declaration of Helsinki for medical research involving human participants and was approved by the Ethics Committee of the University of Würzburg (approval no.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Quality of life and safety of a dietary intervention with French maritime pine bark extract (Pycnogenol®) in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study: Part II

Study design awaiting verification · Frontiers in Nutrition · 2026

Original publication title

Quality of life and safety of a dietary intervention with French maritime pine bark extract (Pycnogenol®) in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study: Part II

Christian Scherg; Franca Genest; Jonas Maghary; Lothar Seefried; Petra Högger

Copyright © 2026 Scherg, Genest, Maghary, Seefried and Högger.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Dietary supplementation with Pycnogenol® maintained physiological blood count, markers of liver and kidney function, thus supporting the favorable safety of the plant extract. Additionally, participants receiving Pycnogenol® experienced significant improvements in pain-related and vitality-related quality of life during the randomized placebo-controlled phase.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

In the pre-therapeutic stage of osteopenia or clinically stable osteoporosis dietary supplements are frequently used, but often evidence for benefits and risks is sparse. The French maritime pine bark extract Pycnogenol® has anti-inflammatory and antioxidative effects. Although beneficial impact on various health conditions has been recorded, no data regarding the impact on quality of life and safety of Pycnogenol® supplementation in osteopenia and stable osteoporosis is available yet.

Source: Introduction

Abstract: What methods does the paper describe?

In a randomized, double-blind, placebo-controlled clinical trial, 67 women received Pycnogenol® (100 mg twice daily; n = 33) or placebo (n = 34) for 3 months, after which all participants took Pycnogenol® for additional 3 months in an active-treatment extension phase. The quality of life was assessed by two validated questionnaires and biochemical safety indicators, including blood count, liver and kidney function, markers of inflammation and mineral metabolism were analyzed.

Source: Methods

Abstract: Results

During the randomized placebo-controlled phase, the SF-36v2 bodily pain score improved in the Pycnogenol® group while remaining unchanged under placebo. This effect persisted after adjustment for baseline values (p = 0.0106). A comparable difference was observed for vitality (p = 0.0282). The total QUALEFFO-41 score did not differ between the groups. In the QUALEFFO-41 pain domain, scores were lower after 6 months in the group treated continuously with Pycnogenol® than in the group switched from placebo (p = 0.0231).

During the intake of Pycnogenol®, the activities of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) remained stable, while a minor decrease in gamma glutamyl transferase (GGT) was significant (p = 0.0141) in the switched-over group. No significant changes were observed regarding blood count, kidney function (glomerular filtration rate GFR; blood urea) and inflammation (C-reactive protein; CRP). Serum phosphate concentrations declined under Pycnogenol® within the reference range, reaching statistical significance after 6 months during the extension phase (p = 0.0039).

Source: Results

Abstract: Conclusion

Dietary supplementation with Pycnogenol® maintained physiological blood count, markers of liver and kidney function, thus supporting the favorable safety of the plant extract. Additionally, participants receiving Pycnogenol® experienced significant improvements in pain-related and vitality-related quality of life during the randomized placebo-controlled phase.

Source: Conclusion
Authors’ abstract

Introduction

In the pre-therapeutic stage of osteopenia or clinically stable osteoporosis dietary supplements are frequently used, but often evidence for benefits and risks is sparse. The French maritime pine bark extract Pycnogenol® has anti-inflammatory and antioxidative effects. Although beneficial impact on various health conditions has been recorded, no data regarding the impact on quality of life and safety of Pycnogenol® supplementation in osteopenia and stable osteoporosis is available yet.

Methods

In a randomized, double-blind, placebo-controlled clinical trial, 67 women received Pycnogenol® (100 mg twice daily; n = 33) or placebo (n = 34) for 3 months, after which all participants took Pycnogenol® for additional 3 months in an active-treatment extension phase. The quality of life was assessed by two validated questionnaires and biochemical safety indicators, including blood count, liver and kidney function, markers of inflammation and mineral metabolism were analyzed.

Results

During the randomized placebo-controlled phase, the SF-36v2 bodily pain score improved in the Pycnogenol® group while remaining unchanged under placebo. This effect persisted after adjustment for baseline values (p = 0.0106). A comparable difference was observed for vitality (p = 0.0282). The total QUALEFFO-41 score did not differ between the groups. In the QUALEFFO-41 pain domain, scores were lower after 6 months in the group treated continuously with Pycnogenol® than in the group switched from placebo (p = 0.0231).

During the intake of Pycnogenol®, the activities of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) remained stable, while a minor decrease in gamma glutamyl transferase (GGT) was significant (p = 0.0141) in the switched-over group. No significant changes were observed regarding blood count, kidney function (glomerular filtration rate GFR; blood urea) and inflammation (C-reactive protein; CRP). Serum phosphate concentrations declined under Pycnogenol® within the reference range, reaching statistical significance after 6 months during the extension phase (p = 0.0039).

Conclusion

Dietary supplementation with Pycnogenol® maintained physiological blood count, markers of liver and kidney function, thus supporting the favorable safety of the plant extract. Additionally, participants receiving Pycnogenol® experienced significant improvements in pain-related and vitality-related quality of life during the randomized placebo-controlled phase.

Clinical trial registration

https://drks.de/search/de/trial/DRKS00026630, identifier DRKS00026630.

Publication and source details

Original title: Quality of life and safety of a dietary intervention with French maritime pine bark extract (Pycnogenol®) in women with osteoporotic bone loss: a randomized, placebo-controlled double-blind study: Part II

Christian Scherg; Franca Genest; Jonas Maghary; Lothar Seefried; Petra Högger

Frontiers in Nutrition · 2026

* Correspondence: Petra Högger, petra.hoegger@uni-wuerzburg.deCopyright © 2026 Scherg, Genest, Maghary, Seefried and Högger.2026Scherg, Genest, Maghary, Seefried and Höggerhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Horphag Research The author(s) declared that financial support was received for this work and/or its publication. This research was supported by an educational grant of Horphag Research to PH and LS. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:29:21.543575+00:00

DOI: 10.3389/fnut.2026.1924081 · PMC13696226